Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BMRN by emailGet an email when BMRN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BMRN, unsubscribe in one click. Privacy
📣 What BMRN Says Is Next
in 2028 · “The Phase 3 ACTION 3 trial is ongoing, with pivotal data expected in 2028.”
Company press release, Aug 6, 2026 · SEC filing
in 2027 · “The Phase 2/3 study is enrolling, with a data update expected in 2027.”
Company press release, Aug 6, 2026 · SEC filing
2H · “Regulatory submissions are anticipated in 2H’26 should the data be supportive, with a potential first-in-class launch in 2027.”
Company press release, May 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BMRN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMRN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.